---
title: Corellia Pipeline
description: Building drug conjugates with multimodal mechanisms of action that provide an impenetrable wall of activity.
---

## Our Pipeline of ADCs

#### Building drug conjugates with multimodal mechanisms of action to provide an impenetrable wall of activity.

Coromip: Unlocking the Full Potential of PI3K/mTOR Through ADC Delivery

- Warhead is PI3K/mTOR inhibitor Omipalisib
- Targets PI3K/mTOR-addicted tumors
- Systemically dose-limited > ADC-enabled
- Designed to unlock the next wave of targeted ADC efficacy

**Axis-Based Dual Payload Discovery Programs leveraging Coromip backbone**

![payload2](https://corellia.ai/hubfs/payload2.png "payload2")

### Our Pipeline of Coromip ADCs

**Indications**

Lead

Discovery

In Vivo

Cyno Tox

Preclinical

ER+/HER2- BrCa*  
mAb Target: TROP2

SacI-81

Ovarian/Endometrial*      
mAb Target: TROP2

SacI-81

Therapeutic Discovery

**EGFRmut NSCLC**  
**mAb Target: TROP2**

SacI-81

**KRASmut NSCLC  
mAb Target: TROP2  
**

SacI-81

Therapeutic Discovery

**TNBC  
mAb Target: TROP2  
**

SacI-81

**HER+ R/R Enhertu BrCa*  
mAb Target: HER2**

Zan-81

Hematologic  
mAb Target: CDH17

Lonca-81

Oncology & Non-Oncology  
mAb Target: Various

Various

Target Validation

CMC, GMP, GLP

Clinical

## Our Therapeutic Programs

#### CO-1024: First in Class of ADCs to Treat Solid Tumors

Despite considerable progress made in the treatment of Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Gastric Cancer, and Pancreatic Cancers with immune therapy, only a fraction of these patients respond with durable responses. CO-1024-directed ADCs offer a new approach to the treatment of these malignancies with a high unmet medical need.

 

### A Franchise of CO-1008 Directed Therapies

 

Patients with Acute Myeloid Leukemia (AML) currently have few therapeutic options that provide a durable response to tumors. Despite considerable progress in treatment for Non-Hodgkins Lymphoma (NHL), a significant population of Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), and B Cell Acute Lymphoblastic Leukemia (B-ALL) tumors are either CD19-negative or relapse as CD19-negative tumors. CO-1008 ADC aims to resolve the unmet medical needs of patients diagnosed with AML, specifically in tumors with MLL/KMT2A fusions.  CO-1008 target expression is driven by MLL/KMT2A fusion products and regulates the hyperinflammatory nature of these tumors.  The CO-1008 target has low toxicity liabilities with expression absent in hematopoietic stem cells and common myeloid progenitors.